X-ZELL among Asia's 20 most innovative health-tech start-ups
Singapore, September 2018 – Galen Growth, a Singapore-based analytics and advisory firm specialising in cutting-edge healthcare technology, has named X-ZELL Inc. as one of the 20 most innovative health technology start-ups in Asia.
Selected to feature in the 2018 edition of Galen Growth’s prestigious Most Innovative HealthTech Start-up in Asia competition, X-ZELL managed to leave behind some 48 contestants and make the final 16 alongside Australian Shark Tank winner, CancerAid, as well as Tencent-backed software company, MedBanks.
Notably, X-ZELL is the only company in the Top 20 actively involved in clinical research and device development, while all other finalists are primarily focused on app/ software development.
X-ZELL CEO, Dr Sebastian Bhakdi, has also been selected to be one 50 up-and-coming health technology entrepreneurs to feature at the Galen Growth Asia 2018 HealthTech Summit in Singapore next month.
About X-ZELL Prostate™
X-ZELL Prostate™ is a liquid biopsy test using tumor-derived circulating cells, including tumor-derived Circulating Endothelial Cells (CEC), as biomarkers to indicate the presence/ absence of clinically significant prostate cancer in small, 8-10mL blood samples. Click here to find out more.